The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs
The nitro-chloromethylbenzindoline prodrug SN29428 has been rationally designed to
target tumour hypoxia. SN29428 is metabolised to a DNA minor groove alkylator via oxygen …
target tumour hypoxia. SN29428 is metabolised to a DNA minor groove alkylator via oxygen …
Old target; new paradigm: Determinants of sensitivity to hypoxia-directed anticancer prodrugs
F Hunter - 2014 - researchspace.auckland.ac.nz
Targeting tumour hypoxia is a long-standing goal in cancer drug development. An approach
developed over the last three decades involves design of hypoxia-activated prodrugs …
developed over the last three decades involves design of hypoxia-activated prodrugs …